美国食品和药物管理局批准了BeiGene公司的Tevimbra与化学疗法治疗PD-L1表达的晚期胃癌. FDA approves BeiGene's Tevimbra with chemotherapy for advanced gastric cancers expressing PD-L1.

美国食品和药物管理局批准了BeiGene公司的Tevimbra药物与化疗联合使用,用于治疗晚期的HER2- 阴性胃或胃食道结癌,表达PD- L1的第一线治疗. The FDA has approved BeiGene's Tevimbra drug in combination with chemotherapy for the first-line treatment of advanced HER2-negative gastric or gastroesophageal junction cancers that express PD-L1. 这一批准是在成功进行第三阶段试验之后作出的,试验显示,与仅化疗相比,总体存活率有所提高。 This approval follows a successful Phase 3 trial showing improved overall survival compared to chemotherapy alone. 在美国,Tevimbra现在被批准进行两种类型的癌症治疗。 Tevimbra is now approved in the U.S. for two types of cancer treatments.